NanoVibronix Provides Year-End 2017 Business Update and Files 10-K

NanoVibronix (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today provided a business update for the year ended December 31, 2017.

As quoted in the press release:

Brian Murphy, Chief Executive Officer of NanoVibronix, commented, “We have now transitioned from an R&D-focused to a fully commercial organization. Towards this end, we achieved a number of major milestones in 2017 that we believe helped lay the foundation for an aggressive sales and marketing push that is now underway in 2018. First, we released successful interim results for two of our existing products, UroShield® and PainShield®, in the fourth quarter of 2017. In one trial, we reported that less than 4% of patients using UroShield developed infections versus 52% in the control group. This initial data has helped attract significant attention, given the fact that catheter-associated urinary tract infection (CAUTI) is a major global health concern and one of the leading causes of hospital acquired infections.”

Click here to read the full press release.